Abstract:VACCINATION IS RANKED AS ONE of the 10 greatest public health achievements of the last century and is the number one contribution to decreased global morbidity and mortality. Pediatric vaccinations have had the most profound impact of any intervention on increasing global child survival, accounting for 3 million pediatric lives saved annually. However, even in the 21st century, vaccinepreventable infectious diseases remain important causes of morbidity and mortality in many areas of the world. Globally, tetanus, measles, and pertussis are the main vaccine-preventable causes of death in children; septicemia and influenza-related pneumonia are among the top 10 causes of death in adults and children worldwide, including the United States. Although US pediatric vaccination rates remain high, there is a small but vocal antivaccine movement concerned about vaccine safety that may affect vaccination efforts in the United States and elsewhere. In adults, vaccinepreventable diseases result in $10 billion in health care costs and more than 30000 preventable deaths annually; however, vaccination rates among adults remain poor and recommended vaccine schedules for US adults are markedly underutilized. Extending the success of childhood immunization programs to adult populations is therefore a major public health challenge, and recent misconceptions regarding vaccine safety may affect adult immunization initiatives as well. The challenges of developing vaccines against agents of bioterrorism add an important and complex dimension to monitoring safety in vaccine development. Recommended Pediatric and Adult Vaccination Schedules The US organization that determines pediatric and adult immunization policy and guidelines is the Advisory Committee on Immunization Practices (ACIP), an advisory group to the US Public Health Service and the Centers for Disease Control and Prevention (CDC). The ACIP includes representation from pediatric and general medical organizations and community advocates. The American Academy of Pediatrics and the American Academy of Family Physicians also develop separate ongoing pediatric and adult immunization guidelines that harmonize with the ACIP recommendations. Current vaccines recommended for routine use by the ACIP for pediatric and adult use are outlined in BOX 1, although there are a number of other vaccines available for pediatric and adult use in special circumstances. The US Public Health Service and CDC are assisted in review of new vaccines and new indications for current vaccines by the National Vaccine Advisory Committee, which is composed of academic physicians, public health agencies, and community advocates. Another organization that is critical to development of vaccine policy is the US Food and Drug Administration (FDA), which provides oversight of safety and efficacy claims for new vaccines. Although the FDA is not primarily responsible for vaccine policy, it is the sole US agency responsible for licensure and specific indications for vaccines proposed for use in the United States. Whenever there has been probable or even possible evidence of unacceptable vaccine-related adverse events, these committees and agencies have acted in collaboration to minimize harm and to preserve the public health. Risks and Benefits Rates of vaccine-preventable illnesses in children have reached record low numbers (TABLE). The success of vaccination programs has led to proportionally more concerns regarding vaccine safety than concerns about vaccine-preventable diseases, which would likely become reestablished in the absence of continued vaccination programs. A small number of highly publicized claims, unsubstantiated by valid data, regarding vaccineadverseeventshas furtherheightened the suspicion that some or all vaccines may cause unacceptable adverse events. These suspicions have been bolstered by the lack of experience or exposure to most vaccine-preventable illnesses, such as diphtheria, measles, tetanus, poliomyelitis, or Haemophilus influenzae–related invasive diseases, which were major causes of death and disability only a few decades ago. All vaccines carry some risk of adverse reactions. The majority of adverse reactions to the routinely recommended vaccines are minor and are related to pain, erythema, or inflammation at the injection site. These local reactions are common and may occur in up to 50% of vaccinees. Systemic symptoms such as fever, headache, irritability, or diminished activity are less common; the frequency of systemic symptoms is vaccine-specific. Rarely, moderate to severe reactions to vaccines, such as febrile seizures and allergic reactions, occur at a frequency of 1

[Sacrococcygeal chordoma simulating pilonidal cyst].

Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion.

Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study

Acute kidney injury associated with smoking synthetic cannabinoid

Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA—parent compounds and metabolite identification in blood, urine and cerebrospinal fluid

Clinical toxicology of newer recreational drugs

Blood concentrations of synthetic cannabinoids

“Spice”-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014–2020)

A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids

Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020

Current controversies in vaccination: vaccine safety.

Fatal intoxication involving 2-methyl AP-237

Recreational Drug Overdose—Clinical Value of Toxicological Analysis

[Clinical characteristics of Rasmussen encephalitis with special reference to Japanese experience].

Synthetic cannabinoid receptor agonists: classification and nomenclature

Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015

Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists

On local modularity and interpolation in entailment systems

Comprehensive review of the detection methods for synthetic cannabinoids and cathinones

Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health

Toxicology and Management of Novel Psychoactive Drugs